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Background: Inhaled corticosteroids (ICS) are the primary treatment for persistent asthma. Currently available ICS
have differing particle size due to both formulation and propellant, and it has been postulated that this may impact
patient outcomes. This structured literature review and meta-analysis compared the effect of small and standard
particle size ICS on lung function, symptoms, rescue use (when available) and safety in patients with asthma as
assessed in head-to-head randomized controlled trials (RCTs).
Methods: A systematic literature search of MEDLINE was performed to identify RCTs (1998–2014) evaluating standard
size (fluticasone propionate-containing medications) versus small particle size ICS medication in adults and children
with asthma. Efficacy outcomes included forced expiratory volume in 1 s (FEV1), morning peak expiratory flow (PEF),
symptom scores, % predicted forced expiratory flow between 25 and 75% of forced vital capacity (FEF25–75%), and
rescue medication use. Safety outcomes were also evaluated when available.
Results: Twenty-three independent trials that met the eligibility criteria were identified. Benefit-risk plots did not
demonstrate any clinically meaningful differences across the five efficacy endpoints considered and no appreciable
differences were noted for most safety endpoints. Meta-analysis results, using a random-effects model, demonstrated
no significant difference between standard and small size particle ICS medications in terms of effects on mean change
from baseline FEV1 (L) (−0.011, 95% confidence interval [CI]: −0.037, 0.014 [N = 3524]), morning PEF (L/min) (medium/
low doses: −3.874, 95% CI: −10.915, 3.166 [N = 1911]; high/high-medium doses: 5.551, 95% CI: −1.948, 13.049 [N = 749])
and FEF25–75% predicted (−2.418, 95% CI: −6.400; 1.564 [N = 115]).
Conclusions: Based on the available literature, no clinically significant differences in efficacy or safety were observed
comparing small and standard particle size ICS medications for the treatment of asthma.
Trial registration: GSK Clinical Study Register No: 202012.
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Asthma is a common chronic lung condition characterized
by inflammation of the airways, and defined by episodes of
wheezing, chest tightness, shortness of breath, and
coughing [1]. Treatment with regular daily inhaled corti-
costeroids (ICS) is highly effective at reducing symptoms
and the risk of asthma exacerbation and is the primary
therapy for control of chronic asthma in both adults and
children [1]. The clinical effects of daily ICS are recog-
nized in national and international guidelines as they
eliminate or reduce chronic symptoms of asthma, pre-
vent exacerbations, maximize lung function, reduce the
need for rescue β2-agonist treatment, and enable nor-
mal activity with few side effects at low and medium
dose [1, 2].
Delivery of drug to the lungs is influenced by a num-
ber of factors including inspiratory flow and particle size.
Current aerosol delivery systems generally deliver poly-
dispersed aerosols with the majority of particles in the
range 1–5 μm in diameter [3]. Particles <1 μm are
generally exhaled while most particles >5 μm are usually
deposited in the upper airways. However, altering the
characteristics of the aerosol even within this narrow win-
dow of 1–5 μm can alter the pattern of deposition within
the lungs. As control of asthma by ICS requires delivery
to both small and large airways, the differing particle
size of ICS medications could potentially impact both
efficacy and safety outcomes [4, 5]. Traditional chloro-
fluorocarbon (CFC) pressurized metered dose inhalers
(pMDIs) were all suspension-based formulations but
following the CFC transition and the advent of hydro-
fluoroalkane (HFA) propellants, a variety of new
suspension-based and solution-based formulations have
been developed. Solution-based pMDIs differ from
traditional suspension-based pMDIs in that the respirable
particles are only generated after actuation as the propel-
lant evaporates from the liquid plume [6, 7]. The charac-
teristics of the particles generated with solution-based
pMDIs vary from formulation to formulation, with some
generating extra-fine particles with mass median aero-
dynamic diameter (MMADs) of <2 μm while others
generate particles with MMADs more comparable with
traditional HFA-suspension pMDIs (MMADs of 2–5 μm).
Two of the most widely prescribed ICS treatments are flu-
ticasone propionate (FP) and beclometasone dipropionate
(BDP), which are chemically and structurally similar but dif-
fer in their pharmacodynamic properties [5]. For patients
not controlled on ICS alone, both the United States and
European guidelines recommend the additional use of a
long-acting β2-agonist (e.g. salmeterol, formoterol, etc.) in
a fixed-dose combination device. FP and FP/salmeterol
(FP/SAL) are formulated as HFA-suspensions, while
BDP, BDP-formoterol (BDP-F), and a more recent ICS,
ciclesonide (CIC) are formulated as HFA-solutionswhich generate extra-fine aerosols [5]. Thus, FP and
FP/SAL are considered standard particle size ICS
(2–5 μm), while BDP, BDP-F and CIC are considered
small particle ICS (<2 μm).
It has been postulated that the use of ICS medica-
tions with a smaller particle size may confer additional
clinical benefits to patients with asthma compared with
medications with particles of a standard size as they are
able to access the smaller airways resulting in increased
efficacy [8].
The objective of this systematic literature review and
meta-analysis was to evaluate the impact of particle size
on clinical outcomes of patients with asthma by comparing
the effect of small and standard size particle ICS on
lung function, symptoms, rescue use (when available)
and safety as assessed in head-to-head randomized con-
trolled trials (RCTs).
Methods
Details on the methods of the analysis and inclusion cri-
teria were specified in advance and documented in a
protocol (GSK Clinical Study Register ID: 202012, data
on file), and are summarized below.
Inclusion criteria, information source, search and study
selection
Studies eligible for inclusion in the systematic review
were published RCTs comparing FP-containing therapy
(standard particle size) with ICS preparations of small par-
ticle size in adults and children with asthma. Specifically,
treatments evaluated included FP and FP/SAL versus ICS
small particle size comparators (BDP, BDP-F or CIC).
Abstracts for potential inclusion in the systematic re-
view were identified from the MEDLINE database using
the following search terms in PubMed: disease: asthma;
exposure: fluticasone, Flovent®, Flixotide®, Advair®, Seretide®.
Abstracts in English published between January 1, 1998
and January 13, 2014 were considered.
All identified citations were downloaded and duplicate
citations were removed to yield a number of unique hits.
Citations were assessed in a multi-stage screening
process as outlined in Fig. 1. During Screening Stage
One, studies/abstracts were excluded if they included
only patients with allergic rhinitis, compared ICS medi-
cations other than FP or FP/SAL versus BDP, BDP-F, or
CIC, were placebo-controlled, were not a primary epide-
miologic/clinical study or were considered ‘gray litera-
ture’ (meeting abstracts, letters, websites). Other
exclusion criteria included: restricted population (e.g.
pregnant women); comparisons of the same ICS at dif-
ferent dosages; no efficacy or safety data. Citations were
designated as ‘Exclude’, ‘Include’ or ‘Doubt’ and a record
of these decisions was maintained. Abstracts marked as
‘Doubt’ were cross-reviewed by a second epidemiologist.
Fig. 1 Flow diagram showing implementation of search and screening strategies. BDP, beclometasone dipropionate, BDP-F, beclometasone
dipropionate/formoterol fumarate; CIC, ciclesonide; FP, fluticasone propionate; FP/SAL, fluticasone propionate/salmeterol; ICS, inhaled
corticosteroid
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identified as ‘Include’ in Screening Stage One were
reviewed and screened against the exclusion criteria
listed above. The remaining studies were utilized for
extraction.
Data extraction and data items
Study/patient characteristics and interventions were
abstracted from the selected studies. Information on
the following efficacy outcome measures were also
extracted: forced expiratory volume in 1 s (FEV1),
morning peak expiratory flow (PEF), asthma symptom
scores (on 4–9-point scale where a lower score corre-
sponded to fewer symptoms), % predicted forced ex-
piratory flow between 25 and 75% of forced vital
capacity (FVC; FEF25–75%), and rescue medication use
per day. In addition to the common lung function
measure in asthma studies (FEV1 and PEF), FEF25–75%
was chosen as an efficacy measure as it is a more sensitive
indicator for small airway obstruction than FEV1 [9], and
thus more likely to demonstrate variations in efficacy if
the smaller particles were meeting the small airways.
To characterize available safety data, the following end-
points were considered: any adverse events (AEs; at
least one), local steroid effects (oral candidiasis, hoarse-
ness), upper respiratory tract infections, growth and
bone metabolism, and serum cortisol levels to assess
adrenal suppression.
Assessment of risk of bias
Funnel plots were used to detect biases in the identifica-
tion and selection of studies. The funnel plot is atechnique used to investigate the possibility of biases in
the identification and selection phases. In a funnel plot,
the estimated effect size of the intervention from indi-
vidual studies (mean difference) is plotted on the hori-
zontal axis against the standard error of the intervention
effect estimate or sample size on the vertical axis. If
there are no biases, the graph will tend to have a sym-
metrical funnel shape centered on the average effect of
the studies. All studies were included and additional
sources of bias were not formally assessed.Planned analysis and statistical methods
Aggregated clinical data from the completed systematic
review were summarized in standardized electronic ex-
traction forms, with comparative data also entered into
spreadsheets. Clinical statisticians transferred relevant
extracted data into SAS (Statistical Analysis Software,
Cary, NC) or R (R Foundation for Statistical Computing,
Vienna, Austria) for calculation of appropriate statistics
and data displays.
The objective of this analysis was to determine if there
were any clinically significant differences in the com-
parative efficacy or safety of FP-containing medications
with smaller particle ICS-containing comparators; this
was evaluated in the form of a benefit-risk interval plot
and/or meta-analysis, when appropriate. The data were
extracted on the intent-to-treat (ITT) population as de-
fined in each individual trial. The original publications
gave treatment doses as either emitted or delivered;
these same doses were reported within this manuscript
for consistency.
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treatment differences between FP-containing formula-
tions and small particle ICS, including 95% confidence
intervals (CI). For continuous measures, adjusted mean
differences were used, when available. When standard
errors (SE) and/or CIs were not directly available, they
were estimated using available data [10]. For binary mea-
sures, the absolute risk difference and its 95% CI were cal-
culated using the normal approximation to the binomial
distribution.
Formal meta-analysis was conducted for efficacy end-
points when there was sufficient sample size and homo-
geneity across trials. Due to this approach, there was no
adjustment for multiple testing. If there was no signifi-
cant evidence of heterogeneity across the studies, both
fixed and random effects models were performed. The
statistical heterogeneity of the meta-analysis was
assessed by means of the Cochran Q, chi-square test and
the I2 statistic with 95% CI. When the assessments such
as Cochran Q or chi-square test showed that heterogeneity
existed, the results of the random effects model were
selected. Results in children (12 years and younger) and
adolescents/adults were analyzed separately. Meta regres-
sion was used to adjust for differences across studies as ap-
propriate. Additional sensitivity analyses were performed
when appropriate.
Where meta-analysis was not feasible, benefit-risk
interval plots were produced to visually display the esti-
mated differences between treatments and their 95% CIs
for different endpoints on the same graph across studies;
irrespective of differences in study designs, endpoints
and units.Results
The search of the PubMed database identified 1655 po-
tentially relevant articles: 1567 were excluded, mainly
because they were placebo-controlled, evaluated allergic
rhinitis or did not evaluate an ICS of interest; 88 full-
text articles were reviewed and 23 RCTs were included
in the final analysis (Fig. 1) [4, 11–32].
Eight studies evaluated FP versus BDP, 11 evaluated
FP versus CIC, one evaluated FP/SAL versus BDP and
three evaluated FP/SAL versus BDP-F (Table 1). No
studies evaluating FP versus BDP-F and FP/SAL versus
BDP or CIC were identified. Information for children (6
to 15 years in age) was only available in four studies
[15, 18, 26, 27]; one of which utilized a spacer in each
arm [18]. No other studies (adults or children) were
found to use a spacer.
The main efficacy endpoints evaluated in the studies
were FEV1 and PEF (Table 1). The predominant safety
endpoints were overall incidence of AEs and urinary cor-
tisol levels.Fluticasone propionate versus beclometasone
dipropionate
In the eight identified trials comparing conventional
suspension-based FP pMDIs with the ‘ultra fine’ solution-
based BDP formulations similar doses have been used in
each arm (Table 1). This is in accordance with GINA
guidelines reporting the clinically comparable doses of
HFA-FP and HFA-BDP [1]. Hence these comparisons will
address the issue of whether differences in particle size
results in a change in the efficacy or safety profile.
The majority of the RCTs reported no significant dif-
ference in efficacy outcome measures between FP and
BDP. Two of the eight RCTs reported significant differ-
ences in FEF25–75% between FP and BDP; one demon-
strating improvement with FP [18] and the other with
BDP [16] (Table 1).
The majority of RCTs reported no significant differ-
ence in AEs or other safety markers between the two
treatments. Overnight urinary cortisol/creatinine pro-
duction was suppressed more in patients using BDP
compared with patients on FP (1000 μg/day FP versus
BDP: geometric mean fold difference 1.97 [95% CI:
1.28, 3.02]; p < 0.05) [12]. No significant difference was
found in cortisol levels in three studies, either in levels
at the end of the treatment period or in change from
baseline [11, 13, 14].
Fluticasone propionate versus ciclesonide
With few exceptions in 10 identified RCTs, CIC was
found to be non-inferior or not statistically different
from FP for numerous efficacy endpoints (Table 1).
Notably, in a trial by Pedersen et al. in children aged 6–11
years, non-inferiority of CIC to FP (88 μg twice daily) was
observed with regard to change in FEV1 from baseline
over 12 weeks of treatment with 160 μg but not 80 μg
once daily [27]. A similar trial in children aged 6–15 years
comparing the same doses found that CIC did not show
non-inferiority in the change from baseline in morning or
afternoon PEF following 12 weeks of treatment [26]. One
trial of adult patients, by Cohen et al., found greater
improvement in lung function among patients receiving
FP compared with patients receiving CIC, specifically in
mean ± SD % predicted FEV1 (0.5 ± 4.3 versus −3.0 ± 4.6,
respectively; p = 0.021) and FEF25–75% (0.6 ± 5.6 ver-
sus −3.6 ± 6.0, respectively; p = 0.034) [4].
Results for differences in urinary cortisol levels (ad-
justed for creatinine) were variable, with greater adrenal
suppression among patients receiving FP (compared
with CIC) reported in an ITT analysis restricted to pa-
tients with normal creatinine levels (p = 0.006) [26]. In a
small crossover study, patients on FP 2000 μg/day had
significantly lower mean overnight 10-h urinary cortisol
than patients on CIC (CIC versus FP: geometric mean
fold difference 1.5 [95% CI: 1.1, 2.0]; p < 0.05) [24]. One
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scale, and observed that patients on CIC had either a
smaller increase in perceived side effects or a decrease
over the treatment period from baseline compared with
patients receiving FP (between-treatment least squares
mean (±SE) in total Inhaled Corticosteroid Question-
naire Scores: CIC 320 μg once-daily versus FP 200 μg
twice-daily (12 weeks): −2.52 ± 0.82, p = 0.0011; CIC
320 μg twice-daily versus FP 500 μg twice-daily
(24 weeks): −2.05 ± 0.79, p = 0.0047 [28].
Fluticasone propionate/salmeterol versus beclometasone
dipropionate
One trial was identified that compared the efficacy of
BDP (400 μg/day) and FP/SAL (200 μg/100 μg/day) as a
step-down therapy after high-dose ICS (dry powder in-
haler [DPI]-BDP 2000 μg/day) (Table 1) [29]. Lung func-
tion measures were compared between treatment groups
at the end of the 8-week treatment period instead of
comparing the change from baseline in each group.
Methacholine PD20, post-study FEV1 (measured and %
of predicted), morning and afternoon PEF were all sig-
nificantly greater in patients on FP/SAL than in patients
on BDP (methacholine PD20 (μg): 149.9 [95% CI: 114.3,
196.5] versus 71.2 (95% CI: 54.7, 92.8]; FEV1 (L): 2.46
[95% CI: 2.39, 2.53] versus 2.26 [95% CI: 2.20, 2.33],
p < 0.05; FEV1 (% predicted): 77 [95% CI: 75, 79] ver-
sus 70 (95% CI: 68, 72], p < 0.05; morning PEF (L/min):
434 [95% CI: 424, 445] versus 402 [95% CI: 391, 411],
p < 0.05; evening PEF (L/min): 436 [95% CI: 425, 446]
versus 408 [95% CI: 398, 418]; p < 0.05). No differences
were found in FEF25–75%, symptom scores, or reliever
medication use [29]. No significant differences were found
between treatment groups for serum cortisol levels,
urinary cortisol/creatinine ratio, or serum osteocalcin [29].
Fluticasone propionate/salmeterol versus beclometasone
dipropionate-formoterol
Three RCTs compared the efficacy of FP/SAL with BDP-F
(Table 1) [30–32]. One trial in adults with asthma found
significantly greater improvement in FVC in patients
receiving BDP-F than in those receiving FP/SAL (0.46
± 0.51 L versus 0.34 ± 0.44 L, respectively; p = 0.040);
however, no differences were found for any other effi-
cacy parameters [30].
Two RCTs were identified that compared the safety of
BDP-F with FP/SAL; no differences in AEs or urinary
cortisol/creatinine ratio were observed between the two
treatments [30, 31].
Meta-analysis
Meta-analysis methods could only be applied for the effi-
cacy endpoints of FEV1, PEF, and FEF25–75% (Fig. 2).
Other efficacy and safety endpoints were not consideredfor the meta-analysis due to heterogeneity, potential
publication bias, and disparity of endpoint definitions
and/or timing of collection. In adults, the random effects
models showed no significant differences between small
and standard size particle ICS for change in FEV1
(−0.011 L, 95% CI: −0.037, 0.014; p = 0.394), or FEF25–75%
(−2.418, 95% CI: −6.400, 1.564; p = 0.234) (Figs. 2a and c).
Meta-regression analysis showed that the only treat-
ment effect modifier present for morning PEF was dose
level (high versus low); however, high dose versus
medium dose or high hose versus high-medium dose did
not show a statistically significant difference. This sug-
gested that it may not be appropriate to use either meta-
regression or meta-analysis with all of the data in the
final model. Instead, the morning PEF endpoint was ana-
lyzed as two separate subgroups (high/high-medium
doses and medium/low doses). The random effects
models showed no significant differences between small
and standard size particle ICS for change in morning
PEF (medium/low doses: −3.874 L/min, 95% CI:
−10.915, 3.166; high/high-medium doses: 5.551 L/min,
95% CI: −1.948, 13.049) (Figs. 2bi and ii).
For each endpoint, the heterogeneity test showed that
there was no between-study variation, suggesting that
fixed effects models were also appropriate. The random
effects models, which provide a more conservative ap-
proach, were retained as primary models. Similar to the
random effects model, no significant differences were
observed for change in FEV1 and morning PEF using a
fixed effects model (p = 0.394 and p = 0.097, respectively).
Even though the analysis of both data subgroups for the
morning PEF data led to the same conclusion, the results
for the mean differences between medium/low
(−4.223 L/min) and high/high-medium (5.551 L/min)
dose levels appeared to be in opposite directions
(Figs. 2bi and ii). Treatment differences in FEF25–75%
were found to be significantly in favor of FP using a
fixed effects model (−2.853 L/min; 95% CI −5.579,
−0.127; p = 0.040), though not in the random effects
model (−2.418, 95% CI: −6.400, 1.564; p = 0.234)
(Fig. 2c). The heterogeneity test and I2 (p-value = 0.174
and I2 = 39.6%) showed no significant between-study-
variation. However, definitive conclusions could not be
drawn from these treatment differences due to the
small number of studies (N = 4) evaluated, which also
explains the wider CIs for the results of the random ef-
fects model. In children, the small number of studies
with disparate endpoints and results did not allow for
meta-analysis.
Sensitivity analyses were performed for FEV1, the
high/high-medium dose subgroup data for morning PEF,
and FEF25–75%, by excluding trials with crossover design
[23] or with multiple arms (only in the case of FEV1)
[25]. The results of the sensitivity analyses for FEV1 and
a)
b)
c)
N
N
N
N
Fig. 2 (See legend on next page.)
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Fig. 2 Pooled effects for efficacy endpoints with 95% CI of eligible studies comparing small versus standard size particle ICS medications. Mean
difference in change from baseline between treatments for (a) FEV1, (b) morning PEF and (c) FEF25%-75%. BDP, beclometasone dipropionate, BDP-F,
beclometasone dipropionate/formoterol fumarate; CI, confidence interval; CIC, ciclesonide; FEF25–75%, % predicted forced expiratory flow between 25%
and 75% of forced vital capacity; FEV1, forced expiratory volume in 1 s; FP, fluticasone propionate; FP/SAL, fluticasone propionate/salmeterol; PEF, peak
expiratory flow
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model. However, the results of the sensitivity analysis for
FEF25–75% (excluding Lee et al. [22]), were found to differ
from the final model. There was a statistically significant
treatment difference between standard size and small
size particles on FEF25–75% in the final fixed effect model
(−2.853 L/min; 95% CI −5.579, −0.127; p = 0.040) but
not in the sensitivity analysis (−2.414 L/min; 95% CI
−5.406, 0.578; p = 0.114). These conflicting conclusions
may be due to small patient sample sizes.
Benefit-risk plots
The benefit-risk plots included effect estimates from all in-
dividual studies included in the analysis of each efficacy and
safety endpoint. For adult/adolescent patients (aged
≥12 years), the effect on total asthma symptom score anda)
(crossover)N
N
N
N
N
N
N
N
N
N =
N =
N =
N =
N =
N =
N =
N =
N =
N =
N =
N =
N =
N =
N =
N =
N
N
N
Fig. 3 Benefit-risk plot in adolescents and adults by particle size. AM, morn
ciclesonide; CO, crossover; FEV1, forced expiratory volume in 1 s; FEF25–75%,
vital capacity; FP, fluticasone propionate; FP/SAL, fluticasone propionate/sal
expiratory flow; PM, eveningrescue medication use was only assessed for FP versus CIC.
No clinically meaningful differences were noted across the
five efficacy endpoints considered (FEV1, morning PEF, and
FEF25–75%, asthma symptoms and rescue medication use)
in both adults (Fig. 3) and children (Fig. 4).
No appreciable differences were noted for most safety
endpoints (AEs, local steroid effects, upper respiratory
tract infections, growth and bone metabolism, and adrenal
suppression) in both adults and children (Figs. 3 and 4);
most studies though were not designed to test treatment
differences for safety endpoints. Patients receiving FP ex-
perienced more local steroid effects at the upper airways
than those receiving CIC; this was likely due to the fact
that CIC is administered as a pro-drug which is only acti-
vated in the lower airways. The cortisol levels data were
variable, with no clear differentiation between treatments.b)
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
ing; BDP, beclometasone dipropionate; CI, confidence interval; CIC,
% predicted forced expiratory flow between 25% and 75% of forced
meterol; hCRF, human corticotropin-releasing factor; PEF, peak
Fig. 4 Benefit-risk plot in children by particle size. BDP, beclometasone dipropionate; CIC, ciclesonide; FEF25–75%, % predicted forced expiratory
flow between 25% and 75% of forced vital capacity; FEV1, forced expiratory volume in 1 s; FP, fluticasone propionate; PEF, peak expiratory flow
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of asymmetry (p-values ranging from 0.225–0.822)
(Fig. 5), the FEV1, morning PEF and PEF25–75% data did
not exhibit asymmetry, which suggests that there is nei-
ther publication bias nor a systematic difference between
smaller and larger studies (‘small study effects’).
Discussion
Summary
In this meta-analysis of studies in adults and adoles-
cents, no significant differences were observed be-
tween standard size (FP and FP/SAL) and small size
(BDP, CIC and BDP-F) particles ICS for change inFEV1, morning PEF or FEF25–75% using the random
effects model. Similarly, no significant differences
were observed between standard size and small size
particles ICS in the subgroup analysis according to
dose for morning PEF. However, it was observed that
the result of the medium/low dose analysis for morn-
ing PEF was slightly in favor of standard particles (i.e.
standard size particles ICS demonstrated better
efficacy) versus small particles while the converse was
true for high/high-medium dose analysis. This
observed difference in the subgroup analyses suggests
that dose level may be the effect modifier for morn-
ing PEF.
a)
b)
c)
Fig. 5 Funnel plots for studies included in the (a) FEV1, (b) morning PEF and (c) FEF25–75% endpoints meta-analyses. a. Linear regression test of
funnel plot asymmetry: t = −0.2342, df = 7, p-value = 0.822. b. Linear regression test of funnel plot asymmetry: t = 1.332, df = 7, p-value = 0.225.
c. Linear regression test of funnel plot asymmetry t = 1.547, df = 6, p-value = 0.262. FEF25–75%, % predicted forced expiratory flow between 25%
and 75% of forced vital capacity; FEV1, forced expiratory volume in 1 s; PEF, peak expiratory flow
El Baou et al. BMC Pulmonary Medicine  (2017) 17:31 Page 13 of 16FEF25–75% was chosen as an efficacy endpoint as it is a
more sensitive indicator for disease in the small airways
than FEV1 [9], and thus more likely to demonstrate vari-
ations in efficacy if the smaller particles were meeting
the small airways. However, there is ongoing debate as
to the role of FEV25–75% values in assessing asthma con-
trol and phenotype-driven treatment [33, 34]. Although
there were no significant differences in FEF25–75% for dif-
ferent particle sizes using the random effect model
(mostly due to the small number of studies), a statisti-
cally significant difference in favor of standard particleswas seen when the fixed effects model was used because
the heterogeneity tests were not significant. However,
this statistical difference was not clinically significant.
In terms of specific treatment comparisons, little or no
differences in (FEV1 and PEF) were reported for FP ver-
sus CIC, FP/SAL versus BDP-F, and FP versus BDP.
There were no significant differences in FEF25–75% for FP
versus CIC; however, evidence of increased efficacy in
FEF25–75% was demonstrated in one trial with FP versus
BDP [18] while the opposite was shown in another [16].
The results of this study also showed no significant
El Baou et al. BMC Pulmonary Medicine  (2017) 17:31 Page 14 of 16differences in asthma symptoms and use of rescue medi-
cations between small and standard size ICS. However,
these results should be treated with caution as these pa-
rameters were only evaluated between FP and CIC and
not for FP versus BDP.
For the safety endpoints considered, no appreciable
differences were observed for most endpoints though it
should be noted that the majority of studies were not
designed to test treatment differences for safety end-
points. Adult/adolescent patients experienced more local
steroid effects with standard particles than small parti-
cles. The observation that the local steroid effects at the
upper airways favored small particles was likely due to
the fact that CIC is administered as a pro-drug which is
only activated in the lower airways. Overall, the cortisol
data were variable with no clear differentiations between
particle sizes.
Particle size, lung deposition, and clinical outcomes
Although there is a relationship between smaller particle
size and increased delivery to the distal lung [35, 36], the
current study demonstrated that increased deposition in
the distal lung does not appear to translate into im-
proved clinical outcomes for patients with asthma.
These results are unsurprising for a number of reasons,
not least because an increased proportion of the inhaled
dose is likely to deposit in the distal respiratory compart-
ment beyond the conducting airways. Based on current
understanding, the effect of using an aerosol with
smaller particle size or a ‘finer’ aerosol is both to
increase the dose reaching the lungs by reducing the
oropharyngeal deposition and to increase the proportion
of that dose depositing distally. While simplistically this
increased distal deposition might be considered to result
in increased deposition in the ‘small airways’, it is im-
portant to recognize the increased deposition in fact
occurs in the respiratory compartment beyond the con-
ducting airways.
In considering the impact of ICS with different particle
sizes it is important to understand the factors influen-
cing the pattern of deposition of an aerosol in the com-
plex 3D structure formed by the conducting airways
(large and small) and pulmonary/alveolar compartments
of the lung. Current mathematical modeling methods
combined with 3D imaging suggest that the vast major-
ity of inhaled aerosol (>90%) inhaled during tidal breath-
ing is delivered to the pulmonary/alveolar compartment
beyond the conducting airways, and this will increase with
the modified inspiratory breath when using a pMDI (with
or without a holding chamber) [37, 38]. Hence for a given
dose administered to the conducting airways (large,
medium, and small), the dose delivered more distally will
be relatively greater with the ‘finer’ aerosol. With such a
small proportion of the aerosol depositing in theconducting airways it is unlikely that there will be a major
change in the concentration of aerosol at the epithelial
surface of the conducting airways. This is particularly true
of the small conducting airways which have a much
greater relative surface area than the more central airways.
Another point of consideration is the conjecture that ‘finer’
aerosols will penetrate more effectively in the face of airways
narrowing. However, any perceived advantage of finer aero-
sols in accessing the blocked/narrowed airways would be
transient in nature as it has been shown that the blockage is
resolved very rapidly in the vast majority of patients with
asthma when they commence ICS treatment [39].
Based on the results of this study and discussions
above, it is evident that the key issue should be the
evaluation of the ‘therapeutic index’ of different drug-
device combinations rather than a comparison of aerosol
particle sizes for controlling asthma. Unfortunately, there
is no robust method for assessing this. As previously men-
tioned, apart from particle size, drug deposition within the
lung is dependent on other factors such as inhaler device
and inhalation technique, which varies between patients
[36, 40, 41]. Thus, these factors make it impossible to
know what lung doses will be achieved when an individual
patient uses a particular drug-device combination, even
under controlled conditions [42]. Consequently current
guidelines advocate titration of ICS dosages against symp-
toms and spirometric data [2]. Using the lowest effective
dose ensures maximum efficacy and minimizes the risk of
side effects. The guidelines do not distinguish between
corticosteroids formulations and this approach is sup-
ported by this systematic review.
A number of observational studies and historical
matched cohort analyses have recently been published
comparing the outcomes and cost of treatment with small
versus standard size particle ICS in patients with asthma
[43–46]. In general, the studies found that asthma treat-
ment outcomes were similar or better with small size par-
ticle ICS (BDP) compared with standard size particle ICS
(FP). However, such studies are usually confounded by
variables that are not present in RCTs. For example, ob-
servational studies often rely on prescription data (which
does not necessarily translate to actual dosage taken) or
are not able to quantify past exposure of some drugs. Fur-
thermore, control for asthma severity in these studies was
often indirect via rescue medication and hospitalizations.
Another factor that might confound the results of these
studies is the lack of patient randomization.
Most of the individual clinical studies included in this
review may not have been powered to detect clinically
meaningful differences but statistically significant differ-
ences. This meta-analysis offered the opportunity to
increase the sample size and power to calculate pooled es-
timates for treatment differences. Despite this increased
power to detect statistical differences, the relevance and
El Baou et al. BMC Pulmonary Medicine  (2017) 17:31 Page 15 of 16clinical meaningfulness of these results must be deter-
mined beyond the results showing statistical significance.
A potential limitation of literature reviews/meta-ana-
lyses pertains to publication bias. Searches of databases
such as PubMed or EMBASE yield long lists of studies
that have been published. Such searches are unlikely to
yield a representative sample because studies that show
a ‘positive’ result are more likely to be published than
those that do not. However, based on the funnel plots
and the test of asymmetry, the FEV1, morning PEF and
FEF25–75% data did not exhibit asymmetry, which sug-
gests that publication bias is not likely to be a limiting
factor in this study.
Another potential limitation is that the present study
did not explore whether other parameters of inflammation
such as fractional exhaled nitric oxide [47] were differen-
tially affected by particle size. Similarly, endpoints such as
asthma exacerbations, which together with lung function
and asthma symptoms indicate sub-optimal asthma con-
trol [1], was also not assessed in the present study.
Conclusion
In summary, the results of this systematic review do not
support the suggestion that smaller size particle ICS are
intrinsically more ‘effective’ than larger standard size
particle ICS on the endpoints of lung function, asthma
symptoms and rescue medication use. Markers of in-
flammation and asthma exacerbation were not assessed
in this meta-analysis and so the ability of small particle
treatments to differentially affect these outcomes were
not possible to ascertain. No study to date has clearly
addressed the key issue of the relative therapeutic index of
the different drug-delivery combinations though there are
robust data that regular (>80% of doses) use of these treat-
ments at licenced doses is effective and well tolerated.
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